A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Hepatocellular Carcinoma
About 60 patients with HCC, who had received complete resection or TACE and got Complete
remission (CR) or partial response (PR), will be randomly divided into group A (receive
DC-CIK treatment) or group B (just regularly follow up), and the randomize ratio will be
1:1. Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks).
Patients in group B will have no anti-tumor therapy.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Guangxi Medical University
China: Ministry of Health